Sign up Australia
Proactive Investors - Run By Investors For Investors

Pearson out in the cold as Deutsche Bank takes a shine to information providers

The information publishing sector is in rude health, according to Deutsche Bank
Data, data, data
Professional services firms are more willing to spend on new products

Deutsche Bank has taken a look at European information providers and come away impressed.

The bank's publishing sector specialist Mark Braley has eschewed watching the World Cup, preferring to meet or speak with a wide range of professional information executives and concluded that the vast majority of professional information markets remain healthy, supported by improving fundamentals.

READ: UBS cuts RELX to ‘sell’

“In a mid-late cycle environment, professional services firms are more willing to spend on new products and B2B [business-to-business] marketing, while companies are launching new work-flow tools, with the cost of development coming down,” Deutsche Bank said.

The bank has 'buy' recommendations for Relx PLC (LON:REL) – the company formerly known as Reed Elsevier – and Ascential PLC (LON:ASCL) but recommends selling Pearson PLC (LON:PSON), despite increasing the latter's target price to 574p from 525p.

Deutsche has a target price of 1,820p on Relx, up from 1,750p previously, while the price target for Ascential has been bumped up to 460p from 425p.

READ: Ascential acquires digital marketing business WARC ahead of revamped Cannes Lions Festival

Shares in Ascential currently trade at 451.4p, down 1.2p on the day, while Pearson currently trades at 913.8p (up 14.4p) and Relx at 1,688p (up 30p).

View full PSON profile View Profile

Pearson plc Timeline

Article
October 21 2015

Related Articles

Email
February 13 2018
The shares are up 50% over the last year as the company's international expansion gains momentum
Clint Eastwood
May 25 2018
The group’s first piece of original content, a documentary called Pandas, premiered on 24 March this year, to positive reviews.
Cello
April 16 2018
Global pharmaceutical R&D is forecast to reach $182bn by 2022 having grown at near 4% annually since 2006

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use